According to a recent LinkedIn post from Vaxinano, the company’s team collaborated with Belgian zoological park Pairi Daiza on a vaccination campaign targeting lethal toxoplasmosis in several primate species. The post notes that roughly 15 Saimiri boliviensis were immunized using Vaxinano’s VXN-TOXO nasal-spray vaccine, including animals listed as critically endangered by the IUCN.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post highlights that VXN-TOXO is positioned as an adjuvant-free, intranasal technology and is described as unique in its category. It further references 2025 data published in the journal Vaccines (Scuotto et al.) indicating no reported adverse events and a 96.7% reduction in toxoplasmosis-related mortality across 20 zoological institutions.
As shared in the post, Pairi Daiza is characterized as one of Europe’s largest zoological parks with a prominent role in conservation, education, and biodiversity protection. The collaboration is framed as an example of the One Health approach, integrating human, animal, and environmental health, which may support Vaxinano’s positioning in specialized animal health and conservation markets.
For investors, the reported field use of VXN-TOXO in a high-profile conservation setting could signal progress toward broader validation and adoption of Vaxinano’s platform. Evidence of large-scale safety and efficacy in zoological institutions may strengthen the company’s credibility with regulators, research partners, and potential commercial collaborators in both veterinary and human health applications.
The emphasis on innovation, absence of adverse events, and mortality reduction could enhance Vaxinano’s differentiation within the vaccine and One Health ecosystem. While the post does not include financial details or formal commercialization milestones, the association with an internationally recognized zoo and peer-reviewed outcomes may improve the company’s visibility and support its longer-term partnering and funding prospects.